PFE · Q2 2025 Earnings
BullishPfizer
Reported August 5, 2025
30-second summary
Revenue grew 10% YoY to $14.65B in Q2, with non-GAAP EPS of $0.78 and gross margin of 76.1%. Management raised FY2025 adjusted EPS guidance to $2.90–$3.10 (from the prior range) while reaffirming the $61–64B revenue band — the EPS raise absorbs a 3SBio in-process R&D charge that would otherwise have driven a $0.30 raise. The signal: the cost program (~$7.7B overall anticipated savings / ~$7.2B net cost savings by end-2027) and a lower effective tax rate (~13.0% vs prior ~15.0%) are doing more of the work than top-line, and management lowered its leverage target to 2.7x to free up M&A capacity to ~$13B.
Headline numbers
EPS
Q2 FY2025
$0.78
Revenue
Q2 FY2025
$14.65B
+10.0% YoY
Gross margin
Q2 FY2025
76.1%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $14.65B | +10.0% |
| EPS | $0.78 | — |
| Gross margin | 76.1% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Global Biopharmaceuticals Business (Biopharma) | $14.305B | +10.0% |
| Primary Care | $5.54B | +12.0% |
| Specialty Care | $4.378B | +7.0% |
| Oncology | $4.387B | +11.0% |
| Pfizer CentreOne (PC1) | $0.328B | +18.0% |
| Vyndaqel family | $1,615M | — |
| Comirnaty | $381M | — |
| Ibrance | $1,049M | — |
| Eliquis | $2,003M | — |
| Paxlovid | $427M | — |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| United States | $8.894B | +13.0% |
| International | $5.759B | +6.0% |
| Adjusted Diluted EPS (Guidance Raised) | $2.90–$3.10 FY2025 | — |
| Anticipated Net Cost Savings Target | $7.2B by end of 2027 | — |
| Effective Tax Rate on Adjusted Income | 13.2% | — |
Management tone
Cost program reframed from defense to offense. What had been characterized as expense discipline necessary to fund the LOE transition is now being positioned as a structural margin driver. Management cited "approximately $7.7 billion in savings by the end of '27 to drive operating efficiencies, strengthening our business with the potential of contributing significantly to our bottom line" — of which ~$7.2B is net cost savings (the press release footnote distinguishes the $7.7B overall anticipated savings from the $7.2B net figure). The shift matters because it tells you cost-out is no longer being "spent" on R&D reinvestment — it's flowing through to EPS, which is why the raise was possible despite revenue being held.
Pipeline language shifted from portfolio maintenance to multi-fold market expansion. On multiple myeloma specifically: "By executing on Magnetis MM6 and L-REXFUS, other ongoing Phase III trials, we aim to achieve label expansion that, if approved, would collectively increase the addressable population approximately five-fold." This is a different vocabulary than the typical "LOE offset" framing — management is now selling label-expansion math, not just revenue replacement math.
Leverage target lowered to unlock M&A, not to delever for safety. "Our gross leverage at the end of the second quarter was approximately 2.7 times which we are now setting as our new target down from three and a quarter times… Our business development capacity is now approximately $13 billion following the 3S Bio deal." Read this as a deliberate signal: Pfizer is telling the market it has dry powder for tuck-ins and intends to use it (oncology, vaccines, internal medicine including obesity, immunology all named as targets).
COVID reframed from unpredictable to forecasted. "Our plan assumes that a large majority of our COVID revenues are forecasted in both Q3 and Q4… we believe it is prudent to maintain our full-year revenue outlook." The implication is that the revenue reaffirmation is essentially a COVID-conviction statement; if Q3/Q4 Comirnaty and Paxlovid land, FY revenue lands.
3SBio 707 elevated from external innovation to platform asset. Management called 707 a candidate to "become a backbone therapy for multiple solid tumor types," is not waiting for Phase 3 ADC readouts before starting combinations, and has a Phase 3 program planned for later this year — aggressive for an asset acquired this cycle.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Truong Nguyen · UBS
What are Pfizer's broad assumptions regarding MFN price impact quantified in guidance, and what is the company sizing for 2025-26 U.S. fall COVID vaccination season given reduced CDC recommendations and payer pullback?
Management declined to provide specific MFN or tariff details due to ongoing active discussions with the administration at the highest levels, citing productive engagement with President Trump, Secretary Kennedy, and Dr. Oz. On COVID vaccines, company expects indications for 65+ population and those under 64 with underlying medical conditions, anticipates no major payer coverage changes, and projects a strong fall season based on supply capabilities, physician/patient activation plans, and strong contract positions.
Chris Schott · JP Morgan
What drove the lowering of target leverage by ~0.5 turns, and will Pfizer pursue smaller or larger M&A deals? Additionally, will the company wait for Phase 3 ADC data before advancing PD-L1/VEGF combination programs?
Target leverage improved to 2.7x from 3.25x due to faster-than-anticipated cash generation post-Seagen acquisition. Company expects smaller deals given $13B capacity (reduced from prior $10-15B due to 3SBio allocation). Management will not wait for Phase 3 ADC readouts; starting Phase 1/2 combinations this year with 3SBio 707, positioning it as potential backbone to replace single-agent PD-1/PD-L1 with 65% ORR in first-line and planned Phase 3 program later this year.
Courtney Breen · Bernstein
What is driving SG&A efficiencies in the operating model across U.S. and ex-U.S., and how do obesity, immunology, and oncology rank in M&A priorities given the $13B capacity?
International improvements achieved by identifying growth drivers (inline and new products) by country, then investing to win on share of voice while reducing non-core assets and markets. U.S. efficiencies driven by: (1) consolidating to single agency partner, (2) major resource reallocation by product and channel, (3) technology deployment reducing cost per new NBRX by ~20% in deployed categories. M&A priorities remain oncology, vaccines, internal medicine (cardiometabolic/obesity), and immunology. Obesity remains high priority due to large market, breaking science, development/commercial capabilities, and significant opportunities in U.S. and especially China.
Evan Sigerman · BMO Capital Markets
Beyond PADCEV, which 2-3 assets from the $42B Seagen acquisition will drive positive IRR, and what market share could PADCEV capture in NSCLC if approved?
Four main assets acquired at ~$2B in revenue expected to grow to $10B by 2030. PADCEV driving near-term value; muscle invasive bladder cancer readouts in 6 months could change standard of care (expanding addressable population from 18K to 28K patients). PADCEV plus pembrolizumab showing 60% ORR overall, 100% response in PD-L1 high expression subgroup. PD-L1V (first-in-class) accelerated to Phase 3 for head/neck cancer with ~60% ORR plus pembrolizumab. New TOPA1 payload ADCs showing encouraging Phase 1 data. Company confident in recuperating investment with good return.
Rajesh Kumar · HSBC
Can Pfizer confirm it can absorb tariff/MFN impacts in 2026-27 as well? Does current leverage flexibility support oncology M&A if needed, or will deployment focus on obesity/immunology?
Company cannot confirm impact absorption for 2026-27; will share implications once definitive information available. Improved leverage target to 2.7x due to strong operational performance; would accept going above 2.7x for compelling M&A and delever over time (as with Seagen). All four therapeutic areas (oncology, vaccines, internal medicine, immunology) remain acquisition targets. Every deal is value-driven; company has strong commercial heritage in internal medicine/immunology and will pursue right opportunity at right price.
What to watch into next quarter
Whether the FY revenue reaffirmation holds in Q3. Management explicitly said the back half depends on COVID volumes; watch Comirnaty and Paxlovid Q3 prints against an implied $32B+ H2 run-rate to hit the midpoint.
MFN/tariff quantification. Management refused to size the July 31 Trump letter impact in guidance commentary. Watch for either a quantified disclosure in Q3 or a guidance revision; ambiguity is the risk.
PADCEV muscle-invasive bladder cancer readout. Management flagged "within 6 months" — a positive readout expands the addressable population from 18K to 28K patients and validates Seagen ROI math.
3SBio 707 Phase 3 program announcement. Management said "later this year." The structure and timing will signal how aggressively Pfizer intends to compete with the next-generation PD-1/VEGF bispecific class.
Net cost savings progress against the ~$7.2B-net-by-2027 target (within ~$7.7B overall anticipated savings). The EPS raise this quarter was opex- and tax-driven; if the savings trajectory slows, the model loses its primary margin lever.
Whether leverage stays at 2.7x or rises with a deal. Management explicitly said it would tolerate a temporary increase for the right asset — a sub-$13B oncology or obesity tuck-in would be consistent with stated strategy.
Sources
- Pfizer Q2 2025 Earnings Press Release (SEC EX-99): https://www.sec.gov/Archives/edgar/data/78003/000007800325000136/pfe-06292025xex99.htm
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.